What is the significance of a Gleason score of 3 in describing prostate cancer cells?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Gleason score 3 describes prostate cancer cells that are still relatively well-differentiated, meaning they somewhat resemble normal prostate tissue, as noted in the context of prostate cancer diagnosis and treatment 1.

Description of Gleason Score 3

These cells form recognizable glandular structures with distinct borders, though the glands are smaller and more closely packed than normal prostate tissue. Under a microscope, Gleason 3 cells show some variation in size and shape but maintain a generally organized pattern. This score represents low-grade cancer that typically grows slowly and is less aggressive than higher Gleason scores (4 or 5).

Clinical Significance

Gleason 3 is often combined with another score to create a total Gleason sum (such as 3+3=6 or 3+4=7), which helps determine treatment approaches, as discussed in guidelines for clinically localized prostate cancer 1. The Gleason scoring system is important because it helps predict cancer behavior and guides treatment decisions, with Gleason 3+3=6 generally considered the lowest grade of clinically significant prostate cancer.

Treatment Considerations

For patients with a Gleason score of 3, particularly those with a total Gleason sum of 6 (3+3), active surveillance may be a viable option, especially for those with very low-risk disease, as outlined in guidelines for prostate cancer management 1. However, the decision for treatment should be individualized, taking into account the patient's overall health, preferences, and the specific characteristics of the cancer.

Recent Guidelines

Recent guidelines, such as those from the AUA/ASTRO/SUO, emphasize the importance of risk stratification and shared decision-making in the management of clinically localized prostate cancer, including the use of Gleason scoring to guide treatment decisions 1.

From the Research

Description of Gleason Score 3

  • The Gleason score is a system used to grade the aggressiveness of prostate cancer based on the tumor's microscopic appearance 2.
  • A Gleason score of 3 refers to a specific pattern of cancer cell growth, with a score ranging from 2 to 10, where higher scores indicate more aggressive cancer 2.
  • Gleason score 3+3=6 is considered a low-grade cancer, but it is not benign and has the potential to infiltrate the prostate gland and spread to other areas 2.

Characteristics of Gleason Score 3

  • Gleason score 3 is characterized by a specific histological pattern, with cancer cells forming small, well-defined glands 2.
  • This pattern is considered to be an early stage of cancer development, with a lower risk of metastasis compared to higher Gleason scores 2.
  • However, Gleason score 3+3=6 cancer can still progress and require treatment, and its prognosis is influenced by various factors, including the patient's overall health and the presence of other health conditions 3, 2.

Clinical Significance of Gleason Score 3

  • The Gleason score is an important factor in determining the prognosis and treatment of prostate cancer, with higher scores indicating a poorer prognosis 4.
  • A Gleason score of 3 is often associated with a more favorable prognosis, but it is still important to monitor the cancer closely and consider treatment options 3, 4.
  • The Gleason score is used in combination with other factors, such as the patient's PSA level and the stage of the cancer, to determine the best course of treatment 5, 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.